MindWalk Holdings Corp. (NASDAQ:HYFT) Stock Has Consensus Target Price of $5.00 According to Brokerages

MindWalk Holdings Corp. (NASDAQ:HYFT) has earned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $5.00.

Several analysts recently issued reports on HYFT shares. Wall Street Zen upgraded shares of MindWalk from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research note on Monday, July 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. Finally, Zacks Research raised shares of MindWalk from a “strong sell” rating to a “hold” rating in a research note on Monday, September 21st.

Institutional Trading of MindWalk

A hedge fund recently bought a new position in MindWalk stock. BlackRock Inc. purchased a new position in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned 0.33% of MindWalk as of its most recent SEC filing. 6.70% of the stock is owned by hedge funds and other institutional investors.

MindWalk Price Performance

NASDAQ:HYFT opened at $1.50 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84. The stock has a market cap of $69.83 million, a PE ratio of -5.75 and a beta of 0.77. The stock has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.39. MindWalk has a one year low of $0.99 and a one year high of $2.99.

MindWalk (NASDAQ:HYFT) last posted its earnings results on Monday, September 14th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $3.25 million. MindWalk had a negative net margin of 105.11% and a negative return on equity of 133.26%. Equities research analysts expect that MindWalk will post -0.28 EPS for the current fiscal year.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.